| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 1st September 2020 | David A Gonyer | 20,238 | Other acquisition or disposition | $1.05 | $21,249.90 |
| 1st September 2020 | Marilyn R. Carlson | 20,238 | Other acquisition or disposition | $1.05 | $21,249.90 |
| 1st September 2020 | Matthew J D'Onofrio | 20,238 | Other acquisition or disposition | $1.05 | $21,249.90 |
| 2nd March 2020 | Matthew J D'Onofrio | 25,000 | Grant/award etc. | $0.85 | $21,250.00 |
Evoke Pharma
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Evoke Pharma, Inc. develops Gimoti, with promotility and anti-emetic effects. Gimoti is for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
Ticker: EVOK
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1403708
Employees: 5
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
CANbridge Pharmaceuticals Appoints Head of Global Research
26th October 2020
Microsoft quietly prepares to avoid spotlight under Biden
26th October 2020
Microsoft quietly prepares to avoid spotlight under Biden
26th October 2020
HCA Healthcare Reports Third Quarter 2020 Results
26th October 2020
Microsoft quietly prepares to avoid spotlight under Biden
26th October 2020
Microsoft quietly prepares to avoid spotlight under Biden
26th October 2020